

Resource Summary Report

Generated by [NIF](#) on Aug 10, 2026

Australian New Zealand Clinical Trials Registry

RRID:SCR_002967

Type: Tool

Proper Citation

Australian New Zealand Clinical Trials Registry (RRID:SCR_002967)

Resource Information

URL: <http://www.anzctr.org.au>

Proper Citation: Australian New Zealand Clinical Trials Registry (RRID:SCR_002967)

Description: Register of clinical trials being undertaken in Australia, New Zealand and elsewhere including trials from the full spectrum of therapeutic areas of pharmaceuticals, surgical procedures, preventive measures, lifestyle, devices, treatment and rehabilitation strategies and complementary therapies. In 2007 the ANZCTR was one of the first three trial registries to be recognized by the World Health Organisation International Clinical Trials Registry Platform (WHO ICTRP) as a Primary Registry. WHO recognizes registries as Primary Registries if they fulfill certain criteria with respect to data content, quality and validity, accessibility, unique identification, technical capacity and administration. The ANZCTR contributes data to the WHO ICTRP, which was developed in 2007. Trials from all ICTRP Primary Registries can be searched at: www.who.int/trialsearch Studies should be registered prospectively, i.e. before the first patient is recruited. The registry records a trial's * objectives * main design features * sample size and recruitment status * treatments under investigation * outcomes being assessed * principal investigator * contact person
Key points about the ANZCTR * Publicly owned, managed by a not-for-profit organization * All details of trials registered on the ANZCTR are made publicly available * Registration is voluntary, but if a registrant chooses to register a trial, certain fields are mandatory * Registration is free of charge * Responsibility for registration lies with the Sponsor

Abbreviations: ANZCTR

Resource Type: database, data or information resource

Defining Citation: [PMID:23672724](#), [PMID:29915979](#)

Keywords: clinical, clinical trial, registry, pharmaceutical, surgical, lifestyle, treatment, therapy, FASEB list

Funding: National Health and MRC ;
Health Research Council of New Zealand

Availability: Public, The community can contribute to this resource

Resource Name: Australian New Zealand Clinical Trials Registry

Resource ID: SCR_002967

Alternate IDs: r3d100011164, nif-0000-30135

Alternate URLs: <https://doi.org/10.17616/R36S5G>

Record Creation Time: 20220129T080216+0000

Record Last Update: 20260808T190354+0000

Ratings and Alerts

No rating or validation information has been found for Australian New Zealand Clinical Trials Registry.

No alerts have been found for Australian New Zealand Clinical Trials Registry.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 974 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Babbage T, et al. (2026) Effect of a prior hypercapnia experience on recognition of hypercapnia in divers: a randomised controlled study. Diving and hyperbaric medicine, 56(2), 115.

Berthon BS, et al. (2026) Oral lactoferrin reduces systemic inflammation, enhances anti-viral responses and modulates immune cell profiles: a randomised controlled trial in healthy, older adults. The British journal of nutrition, 135(9), 1.

Iqbal A, et al. (2026) Infant Formula for the Prevention and Treatment of Neonatal Hypoglycaemia: A Systematic Review and Meta-Analysis. Acta paediatrica (Oslo, Norway : 1992), 115(1), 32.

Farrell AM, et al. (2026) Very low energy ketogenic diet vs. Mediterranean diet for MASLD: Superior steatosis reduction in a randomised pilot study. JHEP reports : innovation in hepatology, 8(5), 101787.

Coates SS, et al. (2026) Factors influencing referrals amongst allied health and medical practitioners managing people with musculoskeletal conditions in Australian primary care. BMC health services research, 26(1).

Radovic LK, et al. (2026) Predictors of benefits and safety events from participation in a lifestyle therapy trial for adults with depression: A secondary analysis of the CALM randomised controlled trial. *The Australian and New Zealand journal of psychiatry*, 60(7), 677.

Kim GHJ, et al. (2026) Improved quality of life, reduced quantitative lung fibrosis in a trial of inhaled pirfenidone for idiopathic pulmonary fibrosis. *BMC pulmonary medicine*, 26(1).

Felippe ISA, et al. (2026) Vitamin B6 (Pyridoxal 5' Phosphate) antagonises carotid body P2X3 receptors in hypertension. *Cardiovascular research*, 122(2), 285.

Mills L, et al. (2026) The effect of daily aerobic cycling exercise on cannabis withdrawal: An inpatient randomised controlled trial. *Scientific reports*, 16(1).

Smith MC, et al. (2026) Temporal External Validation of the TWIST Prediction Tool for Time to Independent Walking after Stroke. *Neurorehabilitation and neural repair*, 40(6), 461.

Taruc RR, et al. (2026) Videography of pathways for enteric pathogen exposure among children in urban informal settlements in Fiji and Indonesia. *BMC public health*, 26(1).

Glare PA, et al. (2026) Topical RM191A gel for chronic peripheral neuropathic pain: randomized, double-blind, placebo-controlled, crossover pilot study. *Frontiers in pain research (Lausanne, Switzerland)*, 7, 1772899.

Cochrane B, et al. (2026) Breathlessness Matters - Australian Cohort Study Evaluating the Impact of a Multidisciplinary, Home-Based Breathlessness Intervention Service Targeting Patients with Chronic Obstructive Pulmonary Disease (COPD). *International journal of chronic obstructive pulmonary disease*, 21, 570099.

Johnstone C, et al. (2026) Oral oxycodone versus sublingual buprenorphine for postoperative pain control after pelvic exenteration (PROSPER): a pilot, registry-embedded, multi-centre, double-blind, placebo-controlled, randomised controlled trial. *BMJ open*, 16(6), e117594.

Scrivener K, et al. (2026) High-Dose Walking Booster Program Is Feasible for People After Stroke: A Phase II Randomized Trial. *Stroke*, 57(1), 5.

Foerster Y, et al. (2026) Sirolimus for Secondary Prevention of Cutaneous Squamous Cell Carcinoma in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *International journal of dermatology*, 65(5), 952.

Ma OB, et al. (2026) A systematic review and meta-analysis assessing the influence of histone deacetylase 6 inhibition on brain infarction and neurological function following acute ischaemic stroke in rodent models. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism*, 46(3), 625.

Tranter KE, et al. (2026) Inspiratory muscle training for people with spinal cord injury: An implementation study. *Clinical rehabilitation*, 40(7), 972.

Holper S, et al. (2026) A phase 2, randomized, multicenter, double-blind, placebo-controlled trial of S-adenosyl methionine in participants with mild cognitive impairment or dementia due to Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 22(4), e71381.

Mehta A, et al. (2026) Neurointerventional Advances in 2025. *Stroke (Hoboken, N.J.)*, 6(3), e002280.